X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercepharma.com/pharma/jj-inks-another-stelara-patent-settlement-time-fresenius-kabi-and-formycon
https://www.pharmiweb.com/press-release/2022-11-03/broad-acting-antiviral-sars-cov-2-drug-fyb207-shows-longer-half-life-and-improved-efficacy-through-o
https://www.formycon.com/en/press-release/formycon-publishes-details-of-a-previously-undisclosed-pipeline-project-fyb206-is-a-biosimilar-candidate-for-keytruda-pembrolizumab/
https://www.pharmatimes.com/news/european_commission_approves_pharma_trios_ranivisio_1454045
https://www.contractpharma.com/contents/view_breaking-news/2022-08-03/fda-approves-first-biosimilar-to-lucentis/?widget=listSection
https://www.lexblog.com/2022/05/19/teva-receives-approval-for-first-ophthalmology-biosimilar-in-europe/
https://generics.pharmaintelligence.informa.com/GB151893/Whos-Hired-Formycon-Is-Latest-To-Swap-CEO
https://www.dgap.de/dgap/News/corporate/formycon-and-scientists-from-tum-publish-new-data-broadly-effective-sarscov-antiviral-drug-fyb/?newsID=1492660
https://www.bloomberg.com/press-releases/2021-10-18/dgap-adhoc-formycon-concludes-collaboration-and-license-agreement-with-scg-cell-therapy-for-its-covid-19-drug-fyb207-for-the
https://www.bloomberg.com/press-releases/2021-08-11/dgap-news-formycon-reports-on-the-status-of-fyb207-development
Market Place
Share 
